重药控股
(000950)
| 流通市值：86.06亿 | | | 总市值：86.06亿 |
| 流通股本：17.28亿 | | | 总股本：17.28亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 20,612,096,609.18 | 80,561,531,747.38 | 59,692,657,955.53 | 39,779,227,702.93 |
| 营业收入 | 20,612,096,609.18 | 80,561,531,747.38 | 59,692,657,955.53 | 39,779,227,702.93 |
| 利息收入 | - | 0 | - | - |
| 已赚保费 | - | 0 | - | - |
| 手续费及佣金收入 | - | 0 | - | - |
| 二、营业总成本 | 20,226,976,660.08 | 79,839,411,726.2 | 59,058,434,322.35 | 39,271,948,454.85 |
| 营业成本 | 19,127,985,333.13 | 74,572,958,281.08 | 55,254,372,237.51 | 36,688,624,034.36 |
| 税金及附加 | 44,546,150.3 | 197,932,772.83 | 141,878,948.79 | 100,812,118.49 |
| 销售费用 | 483,361,355.08 | 2,400,059,706 | 1,708,321,550.29 | 1,130,619,314 |
| 管理费用 | 399,386,855.68 | 1,583,861,371.92 | 1,131,475,000.09 | 799,736,099.79 |
| 研发费用 | 106,918.22 | 318,557.17 | 8,576,219.24 | 7,050,736.95 |
| 财务费用 | 171,590,047.67 | 1,084,281,037.2 | 813,810,366.43 | 545,106,151.26 |
| 其中:利息费用 | 187,365,511.58 | 1,137,829,179.76 | 861,134,770.5 | 576,856,196.22 |
| 其中:利息收入 | 21,476,986.75 | 85,781,932.94 | 70,254,237.69 | 47,382,746.06 |
| 加:公允价值变动收益 | -861,030.74 | 6,919,028.26 | 7,047,508.39 | 8,905,917.98 |
| 加:投资收益 | 49,857,971.07 | 402,412,494.38 | 241,919,054.21 | 163,900,452.5 |
| 净敞口套期收益 | - | 0 | - | - |
| 汇兑收益 | - | 0 | - | - |
| 资产处置收益 | 521,195.79 | 10,534,476.58 | 1,135,849.98 | 1,158,138.14 |
| 资产减值损失(新) | -2,333,195.83 | -89,974,837.74 | -9,788,650.84 | -89,714.27 |
| 信用减值损失(新) | -226,100,551.55 | -524,008,924.77 | -353,321,296.54 | -260,490,241.66 |
| 其他收益 | 7,816,452.2 | 34,638,779.78 | 26,853,372.65 | 21,862,311.09 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 214,020,790.04 | 562,641,037.67 | 548,069,471.03 | 442,526,111.86 |
| 加:营业外收入 | 1,487,612.65 | 27,011,954.57 | 20,117,320.41 | 13,820,736.19 |
| 减:营业外支出 | 4,176,197.8 | 32,144,744.79 | 21,105,429.92 | 10,254,641.98 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 211,332,204.89 | 557,508,247.45 | 547,081,361.52 | 446,092,206.07 |
| 减:所得税费用 | 38,827,000.41 | 155,716,787.72 | 140,237,633.89 | 103,386,763.93 |
| 六、净利润 | 172,505,204.48 | 401,791,459.73 | 406,843,727.63 | 342,705,442.14 |
| 持续经营净利润 | 172,505,204.48 | 401,791,459.73 | 406,843,727.63 | 342,705,442.14 |
| 终止经营净利润 | - | 0 | - | - |
| 归属于母公司股东的净利润 | 125,235,079.12 | 282,993,622.91 | 292,225,609 | 238,088,559.78 |
| 少数股东损益 | 47,270,125.36 | 118,797,836.82 | 114,618,118.63 | 104,616,882.36 |
| (一)基本每股收益 | 0.07 | 0.16 | 0.17 | 0.14 |
| (二)稀释每股收益 | 0.07 | 0.16 | 0.17 | 0.14 |
| 八、其他综合收益 | - | -21,981,302.9 | -269,117.69 | -652,446.21 |
| 归属于母公司股东的其他综合收益 | - | -20,830,560.64 | -227,271.21 | -550,994.02 |
| 九、综合收益总额 | 172,505,204.48 | 379,810,156.83 | 406,574,609.94 | 342,052,995.93 |
| 归属于母公司股东的综合收益总额 | 125,235,079.12 | 262,163,062.27 | 291,998,337.79 | 237,537,565.76 |
| 归属于少数股东的综合收益总额 | 47,270,125.36 | 117,647,094.56 | 114,576,272.15 | 104,515,430.17 |
| 公告日期 | 2025-04-24 | 2025-04-24 | 2024-10-25 | 2024-08-21 |
| 审计意见(境内) | | 标准无保留意见 | | |